/Investor DB

4BIO Capital — Full Portfolio

16 tracked investments · listed companies and verified rows first

Hornet Therapeuticshornet-tx.comSeed · May 2024 · $5M✓ verified

Hornet Therapeutics is a biotech company developing treatments for Epstein-Barr Virus (EBV) driven diseases, with a lead IDO-1 inhibitor (HTX-201) aimed at preventing EBV-implicated conditions such as post-transplantation lymphoproliferative disease.

BiotechMedical Devices

Christoph Hess(Co-founder (Professor))

March Biosciencesmarch.bioinSeries A · Oct 2024 · $28M✓ verified

March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.

BiotechMedical DevicesHouston, US

Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)

BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)

Co-investorsMission BiocapitalCancer FocusCancer FundFitz Gate VenturesKdT VenturesModi Ventures+2 more

Actitheraactithera.cominSeries A · Jul 2025 · $75.5M

Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Darshan Dalal(Chief Medical Officer)in

Co-investorsBioqube VenturesHadean VenturesInnovestor VenturesM VenturesSofinnova Partners

Araris Biotechararisbiotech.com

Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.

BiotechMedical DevicesBasel, CH

Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in

Co-investorsPureos BioventuresVI PartnersredalpineSamsung Venturesb2ventureKinled Holding

Ascend Advanced Therapiesascend-adv.cominNov 2024

Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.

BiotechHealthtechMedical DevicesMunich, DE

Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)

BoardMichael Beecham(Director)Andrew Kozlov(Director)

Co-investorsCathay HealthDCVC (Data Collective)Monograph Capital PartnersDigitalis Ventures

Code Biotherapeuticscodebiotx.comin𝕏Jun 2022 · $75M

Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.

BiotechDeep TechHealthtechHatfield, US

Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in

BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)

Co-investorsNew Enterprise Associates (NEA)Amgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more

Cytospire Therapeuticscytospire.comSeries A · May 2026 · $83M

Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.

BiotechHealthtech

Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures+1 more

Hornethornet.comin𝕏May 2024

Hornet is a social networking and chat app for gay men and the broader queer community, offering messaging, a content feed, short videos, and discovery features.

ConsumerImpact & Social GoodMedia & EntertainmentSocial

Christof Wittig(Founder)inDamien BrenierinMitchell Geere

Co-investors500 GlobalMoai CapitalVentech China

LUCA Scienceluca-science.comJun 2022

LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.

BiotechDeep TechHealthtechLongevity

Co-investorsAsahi Kasei Corporate Venture CapitalAxil CapitalFast Track InitiativeRemiges Ventures, Inc.Astellas Venture Management LLCDCI Partners Co. Ltd.

Orchard Therapeuticsorchard-tx.comin𝕏

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)

BoardBobby Gaspar(Scientific Founder)in

Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundAgent CapitalBaillie Gifford+3 more

Platanusplatan.usinMay 2023 · $100M

Teambit analyzes code, meeting time, and interactions to measure and improve the performance of software development teams, delivering objective metrics.

AI & Machine LearningDeveloper ToolsSaaS

Paula Enei(Founder)in

Co-investorsGG CapitalDeerfield Management CompanyGeneral CatalystMRL Ventures FundNorwest Venture PartnersNovo Holdings

Trogenixtrogenixbio.cominOct 2025 · $95M

Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesEdinburgh, GB

Ken Macnamarain

Co-investorsACADEMY INVESTORAIN VenturesCalculus Capital Ltd.IQ CapitalLongeVCOld College Capital

ViaNautisvianautis.cominNov 2023

ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.

BiotechDeep TechMedical DevicesCambridge, GB

Co-investorsCambridge Angels groupO2h VenturesOxford Investment Opportunity Network (OION)SCI VenturesOrigin CapitalUCB Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Estuary BioRay TherapeuticsRedpin Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.